Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:00:02 14/01/2026 +04			5-day change	1st Jan Change
1,077.19 ^USD	-0.35%		+1.24%	+0.23%

02:11pm	Polar Capital Global Healthcare Trust beats benchmark; demand "robust"	AN
11:22am	Novo Nordisk expects a temporary international setback amid intensifying competition

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

Published on 12/01/2025 at 07:39 pm +04

MT Newswires

Eli Lilly and Company

-0.35%

Novo Nordisk A/S

-0.70%

Eli Lilly (LLY) is cutting prices again for those who pay cash for introductory doses of the weight-loss drug Zepbound. The lowest dose vial will cost $299 a month, which would be a saving of about $50. It's part of the price war with rival Novo Nordisk. Bloomberg's Madison Muller reports.

Bloomberg videos, provided by MT Newswires

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ELI LILLY AND COMPANY	1,077.19USD	-0.35%	+1.24%	964B
	NOVO NORDISK A/S	380.60DKK	-0.70%	+3.89%	265B

Latest news about Eli Lilly and Company

02:11pm	Polar Capital Global Healthcare Trust beats benchmark; demand "robust"	AN
11:22am	Novo Nordisk expects a temporary international setback amid intensifying competition
11:16am	AstraZeneca: acquires Modella AI to strengthen its oncology research
07:19am	BGI, Roche roll out diagnostic tests for Alzheimer's in China	RE
06:05am	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
04:00am	Eli Lilly and Company Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 02:15 PM
03:07am	Eli Lilly CEO says could be thinking about guiding 2026 more broadly in a range than we have before - JPM Conf	RE
01-14	Sector Update: Health Care Stocks Softer Late Afternoon	MT
01-14	Novo Nordisk flags near-term headwinds in international operations	RE
01-13	Novo Nordisk flags near-term headwinds in international markets	RE
01-13	Sector Update: Health Care Stocks Decline Tuesday Afternoon	MT
01-13	Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company	CI
01-13	Sector Update: Health Care	MT
01-13	Top Midday Stories: Boeing Q4 Deliveries Rise; L3Harris $1 Billion Investment; JPMorgan Chase Q4 Earnings Fall	MT
01-13	AstraZeneca to acquire Modella AI to speed oncology drug research	RE
01-13	FDA Says Novo Nordisk, Lilly Should Remove Suicide Warnings From Weight-Loss Drugs	MT
01-13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
01-13	French Government Says Eli Lilly Made No Contact Regarding Abivax Takeover	MT
01-13	Ro partners with Amgen to study barriers to obesity care, GLP-1 access	RE
01-13	Illumina introduces Billion Cell Atlas, genome-wide genetic perturbation dataset	RE
01-13	US FDA requests removal of suicide warnings from weight-loss drug labels	RE
01-13	US FDA requests removal of suicide warnings from weight-loss drugs	RE
01-13	Illumina unveils dataset to speed up AI-powered drug discovery	RE
01-13	Illumina Introduces Genetic Perturbation Dataset to Further AI Drug Discovery	MT
01-13	Global drugmakers rush to boost US presence as tariff threat looms	RE

Chart Eli Lilly and Company

Duration

Period

LLY: Dynamic Chart

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.4%); - immunology diseases (9.8%); - neurology (3.3%): primarily drugs used in treating depression and schizophrenia; - other (2%). Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).

Employees

47,000

Sector

Pharmaceuticals

Calendar

02-11 - Q4 2025 Earnings Release (Projected)

More about the company